Cognito Therapeutics

Cambridge, MA · Founded 2016 · Privately Held (backing)

Developer of digital therapeutics designed to treat neurodegenerative disorders by modulating brain activity and targeting underlying disease mechanisms associated with cognitive decline. Cognito Therapeutics is based in Cambridge, MA and was founded in 2016. Its last reported valuation was $30 million in Jul 2016. It has raised $264 million across 2 recorded rounds; the latest was a $10.2 million early-stage round in Jun 2024.

Last reported valuation
$30.0M
Oct 2026
Priced at
—
Total raised
$264.4M
Last round
Early Stage VC
Jun 2024

Who backs Cognito Therapeutics?

11 investors
InvestorType
MicroVenturesVenture capital
Morningside GroupVenture capital
IAG Capital PartnersVenture capital
Wilson Sonsini Goodrich & RosatiOther
Starbloom CapitalFamily office
New VintageFamily office
Alzheimers Drug Discovery Foundation—
Apollo Health Ventures—
Benvolio Group—
FoundersX Ventures—
+ 1 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Cognito Therapeutics investors

11 investors are on record for Cognito Therapeutics, including MicroVentures, Morningside Group, IAG Capital Partners and Wilson Sonsini Goodrich & Rosati. By type, the record holds 3 venture capital firms and 2 family offices. The early-stage round in Jun 2024 drew 3 investors.

Free account
More of Cognito Therapeutics with a free account
  • ·The complete investor list: 11 names
  • ·Watch Cognito Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 11 firms already write checks for companies like Cognito Therapeutics. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View